Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 20, 2020
- Accepted in final form September 11, 2020
- First Published December 15, 2020.
Author Disclosures
- Anna Karin Hedström, MD, PhD,
- Nicole Brenner, PhD (nicole.brenner{at}dkfz-heidelberg.de),
- Julia Butt, PhD (j.butt{at}dkfz-heidelberg.de),
- Jan Hillert, MD, PhD (jan.hillert{at}ki.se),
- Tim Waterboer, PhD (t.waterboer{at}dkfz-heidelberg.de),
- Tomas Olsson, MD, PhD* (tomas.olsson{at}ki.se) and
- Lars Alfredsson, PhD* (lars.alfredsson{at}ki.se)
- Anna Karin Hedström, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Nicole Brenner, PhD (nicole.brenner{at}dkfz-heidelberg.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julia Butt, PhD (j.butt{at}dkfz-heidelberg.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jan Hillert, MD, PhD (jan.hillert{at}ki.se),
Dr Hillert received honoraria for serving on advisory boards for BiogenIdec, Celgene, Merck, Sanofi-Genzyme, Novartis and Sandoz
NONE
Received travel expenses and/or honoraria for lectures or educational activities for BiogenIdec, Merck-Serono, Novartis, Sanofi-Genzyme and TEVA
J Neuroimmunology, no compensation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr Hillert research on MS is currently supported by Biogen, Celgene, Novartis, Merck, Roche and Sanofi-Genzyme. In the past Dr Hillert has also received unrestricted research grants from Merck-Serono and Bayer-Schering.
Dr Hillert receives research support from the Swedish Research Council from 2019 to 2021
NONE
Dr Hillert research on MS is supported by the Swedish Brain Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Tim Waterboer, PhD (t.waterboer{at}dkfz-heidelberg.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tomas Olsson, MD, PhD* (tomas.olsson{at}ki.se) and
Advisory boards Biogen 2006- 2020 and Genzyme 2006- 2020, Merck 2016-2020, Roche and Almirall. Novartis 2009-2018. Cellgene 2019 With all of them advice with regard to therapy in multiple sclerosis
NONE
For lectures on Multiple sclerosis, Novartis 2008 and BiogenIdec 2006, 2007, 2008, 2009, 2010 , 2011, 2012 and 2016. Merck 2019. Genzyme 2012 Merck 2017-2020
Co-editor 2006 in Current opinion in Immunology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1)Merck, 2)Biogen, 3)Genzyme, 4) Novartis, 5) Roche and 6) Merck, all for unrestricted MS research.
Tomas Olsson (TO) has received grant support from The Swedish Research council (07488), EU fp7, Neurinox 2012-2016 and combiMS, 2013-2014, Swedish Brain foundation, Knut and Alice Wallenberg foundation.Margareta af Ugglas foundation
NONE
The Swedish Brain foundation TO has also received unrestricted research grants from AstraZeneca.
NONE
NONE
NONE
NONE
NONE
NONE
- Lars Alfredsson, PhD* (lars.alfredsson{at}ki.se)
NONE
NONE
speakers honoraria from Teva and Biogen Idec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Swedish Medical Research Council (K2013-69X-14973-10- 4,2013-2016, Dnr 825-2012-5168, 2013-2015, Dnr 2016- 02349, 2017-2020) and Swedish Council for Working life, Health and Welfare (Dnr 2012-0325,2013-2015, Dnr 2013- 0194 and 2013-0710, 2014-2016, Dnr 2015-00195,2016- 018, 2017-00687), AFA insurance (Dnr 120299, 2013-2016, 160361), Stockholm County Council (Dnr 2016-1376, 2018- 0201)
NONE
Swedish Brain Foundation (FO2015Â0051, FO2016-2017, FO2017- 0076, FO2019-006, FO2020-0077)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Clinical Neuroscience (A.K.H., J.H., T.O., L.A.), Karolinska Institutet, Stockholm, Sweden; Infections and Cancer Epidemiology (N.B., J.B., T.W.), German Cancer Research Center (DKFZ), Heidelberg; Center for Molecular Medicine (J.H., T.O.), Karolinska Institutet at Karolinska University Hospital, Solna, Sweden; and Institute of Environmental Medicine (L.A.), Karolinska Institutet, Stockholm, Sweden.
- Correspondence
Dr. Hedström anna.hedstrom{at}ki.se
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Current and past Epstein-Barr virus infection in risk of initial CNS demyelinationR.M. Lucas, A.-L. Ponsonby, K. Dear et al.Neurology, July 13, 2011 -
Article
Organic solvents and MS susceptibilityInteraction with MS risk HLA genesAnna Karin Hedström, Ola Hössjer, Michail Katsoulis et al.Neurology, July 03, 2018 -
Article
Elevated EBNA-1 IgG in MS is associated with genetic MS risk variantsKarim L. Kreft, Gijsbert P. Van Nierop, Sandra M.J. Scherbeijn et al.Neurology: Neuroimmunology & Neuroinflammation, October 13, 2017 -
Article
Time correlation between mononucleosis and initial symptoms of MSJohn Endriz, Peggy P. Ho, Lawrence Steinman et al.Neurology: Neuroimmunology & Neuroinflammation, February 27, 2017